There is a growing clinical demand in the
wound care market to treat chronic
wounds such as
diabetic foot ulcers. Advanced cell and tissue-based products (
CTPs) are often used to address challenging chronic
wounds where healing has stalled. These products contain active biologics such as
growth factors and
cytokines as well as structural components that support and stimulate cell growth and assist in tissue regeneration. This study addresses the in vitro
biologic effects of a clinically available dehydrated amniotic membrane allograft (DAMA). The broad mechanism of action results from DAMA's
biologic composition that leads to stimulation of cell migration cell proliferation, and reduction of pro-inflammatory
cytokines. Results show that DAMA possesses
growth factors and
cytokines such as
EGF, FGF, PDGFs,
VEGF, TGF-β,
IL-8, and TIMPs 1 and 2. Furthermore, in vitro experiments demonstrate that DAMA stimulates cell proliferation, cell migration, secretion of
collagen type I, and the reduction of pro-inflammatory
cytokines IL-1β,
IL-6, and TNF-α. This study findings are consistent with the clinical benefits previously published for DAMA and other
CTPs in chronic
wounds suggesting that the introduction of DAMA to non-healing, complex
wounds helps to improve the
wound milieu by providing essential structural components,
cytokines, and
growth factors to create an appropriate environment for wound healing.